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Background: Aggressive anti-cancer treatments can result in ovarian failure. Ovarian cryopreservation has been
developed to preserve the fertility of young women, but early graft revascularisation still requires improvement.
Methods: Frozen/thawed sheep ovarian cortical biopsies were embedded in collagen matrix with or without
isoform 165 of vascular endothelial growth factor (VEGF165) and transplanted into ovaries of immunodeficient
mice. Ovaries were chosen as transplantation sites to more closely resemble clinical conditions in which orthotopic
transplantation has previously allowed several spontaneous pregnancies.
Results: We found that VEGF165 significantly increased the number of Dextran-FITC positive functional vessels
3 days after grafting. Dextran- fluorescein isothiocyanate (FITC) positive vessels were detectable in 53% and 29% of
the mice in the VEGF-treated and control groups, respectively. Among these positive fragments, 50% in the treated
group displayed mature smooth-muscle-actin-alpha (alpha-SMA) positive functional vessels compared with 0% in
the control group. CD31 positive murine blood vessels were observed in 40% of the VEGF165 transplants compared
with 21% of the controls. After 3 weeks, the density of murine vessels was significantly higher in the VEGF165
group.
Conclusion: The encapsulation of ovarian tissue in collagen matrix in the presence of VEGF165 before grafting has
a positive effect on functional blood vessel recruitment. It can be considered as a useful technique to be improved
and further developed before human clinical applications in female cancer patients in the context of fertility
preservation.
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Cancer survival in girls and young women has significantly
improved; however, radiotherapy and chemotherapy may
alter ovarian function by reducing the primordial follicle re-
serve. As a result, patient fertility may be impaired and pre-
mature ovarian failure (POF) may occur [1-3]. Therefore,
techniques for female fertility preservation have been* Correspondence: c.munaut@ulg.ac.be
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unless otherwise stated.developed, including oocyte, fertilised embryo, and ovarian
tissue preservation [2,4]. To date, ovarian tissue preserva-
tion remains the optimal procedure for prepubertal girls
who, after cancer remission, may be auto-transplanted
when the desire for pregnancy arises.
Adult ovarian tissue cryopreservation and transplantation
techniques have been successfully performed and have re-
sulted in the birth of 30 children [5,6]. However, this pro-
cedure still needs to be optimised because significant
follicular loss has been observed during cryopreservation
and subsequent grafting [7,8]. Grafting whole ovaries cryo-
preserved with vascular anastomosis may prevent follicleThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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number of drawbacks including a difficult cryopreservation
process, a laborious surgical technique, which does not al-
ways prevent ischemic damage, and the possibility of re-
introducing malignant cells [9,10]. The most important
challenges in the transplantation of cryopreserved ovarian
fragments are tissue ischemia and reperfusion injury
[11,12]. Transient hypoxia during the first 5 days after ovar-
ian tissue transplantation is followed by gradual oxygen-
ation recovery, which is associated with restored
angiogenesis and reperfusion over the next 5 days [13,14].
A reduction in post-transplantation hypoxia and subse-
quent follicular loss could significantly improve ovarian graft
efficiency. Therefore, angiogenic factors have been tested in
cryopreservation and xenotransplantation models.
Sphingosine-1-phosphate (S1P) is a sphingolipid metabolite
that decreases apoptosis and stimulates angiogenesis and
endothelial cell migration. S1P promotes neoangiogenesis in
ovarian transplants and reduces ischemic reperfusion injury
during the days following transplantation in a xenograft
mouse model [15]. In addition, the use of erythropoietin
(EPO) was found to improve early follicle morphology and
stromal cell density in canine ovarian transplants after
8 weeks and to enhance blood vessel density 16 weeks after
xenografting in severe combined immunodeficient (SCID)
mice [16].
The use of growth factors to improve ovarian tissue
survival after grafting has progressed beyond the preclin-
ical stage. Callejo et al. reported the first human live
birth after impregnation with the frozen/thawed ovarian
cortex of the patient and platelet-rich plasma (PRP) [17].
Therefore, it is important to precisely delineate the cyto-
kines that may convey a significant clinical advantage to
ovarian grafting efficiency.
Vascular endothelial growth factor (VEGF), specifically
VEGF-A, is a potent angiogenic factor that stimulates vas-
cular endothelial cell survival, proliferation, migration, and
differentiation. Moreover, some data suggest that VEGF-A
appears to be involved in folliculogenesis with the presence
of VEGF-A receptors in granulosa cells [18]. VEGF is a
disulfide-bonded dimeric glycoprotein that is encoded by a
gene that contains 8 exons. VEGF acts mainly through
binding to VEGF receptor-2 (VEGF-R2) but also binds to
VEGF receptor-1 (VEGF-R1). In addition, alternative spli-
cing creates numerous isoforms, mainly VEGF121, VEGF165,
and VEGF189. VEGF165 (containing exons 1–5, 7, and 8) is
secreted as covalently linked homodimers of 45 kDa with a
basic character and moderate affinity for heparin. VEGF165
can be found in many tissue types in a soluble form or an-
chored to the extracellular matrix, and a minimal amount
of matrix-bound VEGF165 can support endothelial cell
growth [19-22]. We previously demonstrated the beneficial
effect of VEGF111, a highly soluble and diffusible VEGF iso-
form, in an original model of ewe ovarian tissue xenograftsin SCID mice. VEGF111 lacks exons 5–7 and is resistant to
proteolysis [20]. The use of this isoform in a collagen
matrix, which encapsulates the ovarian cortex at the time
of transplantation, was found to improve angiogenesis and
decrease hypoxia, thereby enhancing the preservation of
primary follicles [23].
For this study, sheep ovarian cortex was used due to
ethical barriers and the limited availability of human
ovarian tissue. Sheep ovary is an adequate candidate for
research due to its ovarian architectures (which are simi-
lar to those of human ovarian tissue), limited number of
developed follicles and single ovulation with primordial
follicles distributed superficially in the cortex. Its size is
80% of that of the human premenopausal ovary, and it
has a comparable collagen-dense cortical layer contain-
ing the pool of primordial follicles [24]. The sheep ovary
has been used in many studies [7,25-28].
In this study, using the same xenograft model, we
tested whether VEGF165, which, unlike isoform 111, is
anchored to the extracellular matrix, could improve
ovarian graft survival by extending the exposure of the




The ethics committee of the University of Liège approved
the present study (reference 1156, February 2011). Study
was initiated in March 2011 and terminated in October
2013.
Five ewes (10 ovaries) were obtained from the Ovine
Research Centre (University of Namur, Belgium). Veterinary
euthanised ewes were intravenously injected with T61 1 ml/
Kg (MSD, Belgium), a laparotomy was performed, and ovar-
ies were sampled immediately. The ovaries were placed in
Leibovitz L-15 medium (Lonza, Basel, Switzerland) supple-
mented with 10% normal sheep serum (Hormonology
Laboratory, Belgium) and kept at 4°C during transport (ap-
proximately 1 hour (h)) and during the preparation (ap-
proximately 1 h) of cortical fragments.
Cryopreservation and thawing processes
As previously described [29], ovarian cortical fragments were
prepared by cutting the cortex into pieces (2.5 × 2.5 ×
1 mm) after the medullar tissue was resected. These ovarian
strips were equilibrated in cryopreservative medium that
contained Leibovitz L-15 medium, which was supplemented
with dimethyl sulfoxide 1.5 M (DMSO) (Sigma), 10% nor-
mal sheep serum, and 0.1 M sucrose for 30 min at 4°C.
They were transferred into cryovial tubes (Simport
Scientific, Canada) containing the same medium. The tubes
were cooled in a programmable freezer (CL-8800i System,
Cryologic Pty., Ltd., Australia) and stored in liquid nitrogen
[25]. Ovarian samples were stored in cryotubes for several
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(minimum 2 weeks, maximum 6 months). The cryovial
tubes were kept at room temperature (RT) for 2 min to thaw
and then immersed in a 37°C water bath until the frozen
media melted, approximately 2 to 3 min. After thawing, the
ovarian strips were given three 5 min washes at 37°C in
Leibovitz medium to remove the cryoprotective agents.
Ovarian transplant encapsulation and SCID mouse
transplantation
Ewe ovarian cortical strips were encapsulated in a three-
dimensional type I collagen (Col I) matrix with or without
VEGF165 as previously described [23] and illustrated in
Figure 1. Collagen matrix was prepared by mixing 9 volumes
of Col I (2.4 mg/ml) extracted from rat tail tendons [30], 1
volume of 10X minimal essential medium (Life
Technologies, Belgium) and approximately 0.1 volume of
1 M NaOH to adjust the pH to 7.4 (Figures 1A-B). Agarose
rings (1.5% Agarose VII solution, Sigma, Belgium) were filled
with the first layer of collagen (60 μL) matrix with or with-
out recombinant murine VEGF165 (50 nM, Peprotech,
Rocky Hill NJ, USA, Cat N° 450–32). After polymerisation,Figure 1 Encapsulation of ovarian graft in collagen matrix with and w
tendons. B. Preparation of collagen matrix. C. Adjusting collagen mix to pH
layer of the collagen matrix with or without recombinant murine VEGF165.
collagen matrix with or without recombinant murine VEGF165. H. Agar ringfrozen/thawed ovarian sheep explant (2.5 × 2.5 × 1 mm)
was placed and overlaid by a second layer of Col I (60 μL).
The agar ring was removed before transplantation in mice
(Figures 1C-G).
Eight-week-old female SCID mice (n = 66, Charles River,
Burlington MA, USA) were selected for ovarian xeno-
transplantation because the SCID affected both B and T
lymphocytes (Table 1). After shaving and anaesthesia by
intraperitoneal injection of ketamine (100 mg/kg) and
xylazine (10 mg/kg), a dorsal incision was performed and
a single ovarian cortex, which was encapsulated in colla-
gen gel, was stitched into the right mouse ovary using 7–0
Prolene sutures. To detect functional vessels and possible
anastomoses of sheep and mouse vessels in the grafted
ovary transplant, 200 μl of dextran-fluorescein isothio-
cyanate (FITC, 2.5 mg/ml in PBS) (Sigma-Aldrich, Saint
Louis, MO, USA) was intravenously injected 3 min before
sacrifice. Functional vessels were detected on transplanted
sections with anti-fluorescein Ab (Converter-POD, Roche,
Penzberg, Germany). The animals were euthanized 3 days
or 3 weeks after grafting. Ovarian cortical tissue specimens
were recovered and fixed in 4% formaldehyde.ithout VEGF165. A. Type I collagen was extracted from rat tail
7.4. D. Illustration of agarose rings. E. Filling of agarose ring with a first
F. Frozen/thawed ovarian sheep explant deposit. G. Second layer of
removal before transplantation.





Control VEGF165 Control VEGF165
Number of mice Grafted mice 16 16 16 18
Dead mice 2 1 1 0
Analysed grafted mice 14 15 15 18
IHC performed (data analysed) H&E (follicular quantification and morphology evaluation) X X
Dextran/FITC (functional blood vessels) X X
Dextran/FITC and α-SMA double staining
(mature functional blood vessels)
X X
Species-specific anti-mouse CD31 X X X X
Saffron (fibrosis) X X
X: analysed; IHC: immunohistochemistry.
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Each graft was embedded in paraffin and cut into 5-μm-
thick serial sections. Several immunohistochemistries were
performed after 3 days or 3 weeks of transplantation
(Table 1). Ten sections per transplant, which covered the
entire ovarian fragment, were stained with haematoxylin
and eosin (H&E) and analysed as previously described to
overcome the effect of heterogeneous follicular distribution
within the transplanted ovarian cortex [24]. Only follicles
in which a defined nucleus was visible were counted and
separated into primordial, primary, secondary, or antral fol-
licles according to the classification by Gougeon [31]. In
these slices, follicular quality was evaluated and classified as
normal or abnormal according to the morphological assess-
ment. As previously described [32-34], the integrity of oo-
cytes, granulosa cells, and basement membrane cells was
observed. Follicles were classified as normal when they
contained an intact oocyte and granulosa cells or abnormal
when they contained a pyknotic oocyte nucleus and a
shrunken ooplasm regardless of the presence of disorga-
nised granulosa cells.
The immunohistochemical detection of vascular endo-
thelial cells (CD31), functional blood vessels (dextran-
FITC), and mature blood vessels (α-SMA) was performed
using specific primary antibodies. Murine vascular
blood vessel colonisation in the graft was detected using
species-specific CD31 immunostaining. Incubation in
PBS-BSA 10%, for 30 min at RT, was used to block non-
specific binding sites. CD31 primary antibody (Ab) was
diluted 1:100 in PBS-BSA 1% and incubated for 2 hours
(h ) a t RT (Rat ant i -mouse , ab56299 , Abcam,
Cambridge, United Kingdom), followed by incubation
with the secondary Ab/HRP (AffiniPure rabbit anti-rat
IgG di luted 1 :4 ,000) , ( JAC-31200504 , Lucron
ELITechGroup, Puteaux, France) for 30 min at RT.
Then, the reaction was revealed using DAB+ (K3468,
Dako, Glostrup, Danemark).Through the Dextran-FITC injection given to mice before
sacrificing them, functional blood vessels were observed
after immunostaining using an anti-fluorescein Ab
(Converter-POD, Roche, Penzberg, Germany). Incubation
in PBS-BSA 10%, for 30 min at RT, was used to block non-
specific binding sites. This immunostaining was performed
in one step by using an anti-fluorescein Ab/HRP ready to
use (incubated for 30 min at RT), which directly recognised
the FITC molecule fixed on Dextran injected before sacri-
fice, and the reaction was revealed using DAB+.
Mature functional blood vessels were recognised by
double staining with dextran-FITC and α-SMA Abs.
Incubation in PBS-BSA 10%, for 30 min at RT, was used to
block non-specific binding sites. Staining against dextran-
FITC was performed using an anti-fluorescein Ab/HRP
ready to use (Converter-POD, Roche, Penzberg, Germany),
which was incubated for 30 min at RT, and the reaction was
revealed using DAB+. A second non-specific binding sites
was blocked, by incubation in PBS-BSA 10% for 30 min at
RT, before α-SMA staining was performed using a mouse
anti-αSMA/FITC Ab diluted 1:1,000 in PBS-BSA 1% and in-
cubated for 1 h 30 min at RT (F3777, Sigma-Aldrich, Saint
Louis, MO, USA), followed by application of the AEC sub-
strate chromogen (K3464, Dako, Glostrup, Danemark). In
this double staining procedure, mature functional blood ves-
sels appeared in red (α-SMA) and brown (dextran-FITC).
Fibrosis was evaluated using saffron staining. Incubation
was performed for 10 min at 37°C in 1% saffron solution
(Microm Microtech, Francheville, France) in absolute
ethanol.
Section and fibrosis analysis
Images of whole-tissue sections were digitised at high mag-
nification (100×) to produce virtual images in which the
pixel size was 1.510 μm. Vessels and the contour of the
whole ovarian grafted tissue were drawn manually for each
section. Then, the number of vessels and the surface of the
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ber of vessels was determined according to the surface units
of ovarian grafted tissue. The image analysis was conducted
using MATLAB 7.9 software.
Fibrosis was analysed on the digital images of saffron-
stained slices using ImageJ software (National Institutes of
Health, USA). Digitised colour images were first decom-
posed into three components of red, green, and blue. To
enhance the features of fibrosis, the blue component was
subtracted from the red component. The resulting images
were then binarised using an appropriate threshold. With
this method, pixels that were associated with fibrosis were
assigned a value of 1 and pixels that were associated with
the tissue were given a value of 0. The ratio between the
surface that was occupied by the fibrotic area and the total
surface area of the tissue represented the proportion of fi-
brotic tissue in each transplant.
Statistical analyses
A statistical analysis was performed using GraphPad
Prism software. The Mann–Whitney test was applied for
comparisons between the two different groups. The stat-
istical evaluation of the presence of blood vessels (dex-
tran-FITC- or dextran-FITC/α-SMA-positive vessels)
and the percentage of morphologically normal or abnor-
mal follicles between the groups was performed using
the Fisher’s exact test. Statistical significance was set at
p ≤ 0.05.
Results
Vascularisation of ovarian cortical grafts
Vascularisation in ovarian grafts was evaluated following
an intravenous injection of dextran-fluorescein isothio-
cyanate (FITC) solution 3 min before sacrifice. Functional
blood vessels in the ovarian transplants were detected after
immunohistochemical labelling with FITC (Figure 2A).
Three days after transplantation
Functional (dextran-positive) blood vessels were detected in
53% of the mice (8/15) in the VEGF165-treated group versus
28.6% of the mice in the control group (4/14) (p = 0.26)
(Table 2). In these FITC-positive transplants, functional
blood vessel density was determined using semi-automated
computer-assisted analysis as previously described [35]. A
higher density of dextran-FITC-positive vessels was ob-
served in the VEGF165 group (8.22 ± 2.10 vessels/mm
2) com-
pared with the control group (2.45 ± 1.27 vessels/mm2) (p =
0.03) (Figure 2B). To determine whether these functional
vessels were mature, double immunostaining against
dextran-FITC and alpha-smooth muscle actin (α-SMA) was
performed to detect pericytes and/or smooth muscle cells
(Figure 2C). Among the FITC-positive xenograft transplants
(4/14 in the control group and 8/15 in the VEGF165-treated
group), 50% of the transplants in the VEGF165-treated groupwere positive for α-SMA (4/8). In the control group, no
transplants displayed double positivity (0/4) (p = 0.21)
(Table 2). Double positivity demonstrated anastomosis be-
tween murine and ovine blood vessels, as murine neovessels
within the fragment cannot be mature after only 3 days.
As previously described, vascularisation of xenografted
ovarian tissue results from anastomoses between ovarian
vessels and host vessels, as demonstrated through previous
double staining, and from graft colonisation by murine
blood vessels, termed chimeric vessels [36]. The immunode-
tection of murine CD31 using a species-specific anti-mouse
CD31 antibody (Ab) identified blood vessels that had mi-
grated from the murine uterine horn to the sheep ovarian
graft 3 days post-transplantation (Figure 3A). A higher pro-
portion of ovarian grafts that contained murine-specific
CD31-positive vessels were observed in the VEGF165-treated
group (40%, n = 15) compared with the untreated group
(21.4%, n = 14), but the difference was not significant (p =
0.43) (Table 2). However, no difference in vessel density was
observed between the two experimental groups (0.77 ± 0.28
vessels/mm2 in the VEGF165-treated group versus 0.59 ±
0.41 vessels/mm2 in the control group, p = 0.36) (Figure 3B).
Three weeks after transplantation
In contrast, 3 weeks after grafting, a higher density of
species-specific murine CD31-positive vessels was ob-
served in the VEGF165 group (23.72 ± 14.36 vessels/mm
2,
n = 18) compared with the control group (9.13 ± 3.45
vessels/mm2, n = 15) (p < 0.01) (Figure 3C).
Fibrosis, follicular density, and morphology
Analysis of fibrosis, evaluated using saffron staining, showed
a similar extent of fibrosis in the VEGF165 (53.82 ± 1.45%,
n = 18) and control (50.31 ± 1.2%, n = 15) groups three
weeks after grafting (p = 0.053) (Figure 4A). The analysis of
primordial and primary follicle density in haematoxylin and
eosin (H&E)-stained sections 3 weeks after grafting indi-
cated a predominance of primordial follicles in the graft
(Figure 4B). However, no differences between the treated
and untreated groups in the follicle density of primordial
(1.69 ± 0.42 and 1.44 ± 0.47 follicles/mm2, respectively, with
a total of 2349 follicles analysed, p = 0.33) and primary folli-
cles (0.05 ± 0.02 and 0.05 ± 0.02 follicles/mm2, respectively,
with a total of 65 follicles analysed, p = 0.32) (Figure 4B) or
morphological anomalies of primordial (78.46 and 76.20%
of morphologically normal follicles, respectively, respect-
ively) and primary follicles (62.96 and 57.90% of morpho-
logically normal follicles, respectively) (Figures 4C-D) were
observed. In addition, the low density of secondary and
more mature follicles prevented further statistical analysis.
Discussion
In this study, the effect of VEGF165 on slow-frozen, cryopre-
served ewe ovarian tissue that was grafted into a murine
Figure 2 The analysis of functional blood vessels in ovarian grafts 3 days after transplantation. A. An illustration of functional blood
vessels that were observed using dextran-FITC immunostaining. B. The quantification of FITC-positive vessels in ovarian transplants from the
control and VEGF165-treated groups. In the treated mice, 8 of 15 fragments contained functional vessels compared with only 4 of 14 fragments in
the control mice. C. An illustration of double staining for functional and mature blood vessels in a transplant that was treated with VEGF165. FITC
was stained brown, and α-SMA was stained red. n corresponds to the number of transplanted ovarian fragments that contained functional blood
vessels. Scale bar: 200 μm. *Corresponds to a p value < 0.05. Error bar are SEM (mean standard error).
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plantation. The results of this study suggest that VEGF165
improves angiogenesis in ovarian grafts as soon as three days
post-transplantation. In addition, this treatment enhanced
vessel maturation because 50% of the ovarian transplants
that were impregnated with VEGF165 exhibited mature ves-
sels that were surrounded by alpha-smooth muscle cells.
This rapid reconstruction of blood vessels in ovarian graftsTable 2 Number of ovarian transplants showing functional, m
transplantation
Blood vessels Control mice
Dextran/FITC positive 4/14 (28.6%)
Dextran/FITC and α-SMA Positive 0/4 (0%)
CD31 positive 3/14 (21.4%)
Percentage of ovarian transplants showing functional blood vessels (dextran/FITC p
and α-SMA positive) and murine blood vessels (CD31 positive) 3 days after transpla
Significance was established at a p value < 0.05.is important for limiting ischemic injury, which has been
demonstrated to induce the depletion of 60-95% of the fol-
licular reserve, including the loss of virtually the entire popu-
lation of growing follicles, during autograft processes
[7,37-39]. This phenomenon has been associated with a dra-
matic reduction in graft size and significant fibrosis [40]. In
this study, three weeks after transplantation, the extent of fi-
brosis was similar between the control and VEGF165-treatedature functional and murine blood vessels 3 days after




ositive), mature functional blood vessels (double staining dextran/FITC
ntation in the VEGF165 treated group and control group.
Figure 3 - Murine blood vessels in sheep ovarian transplants after 3 days and 3 weeks reflect colonisation by host vessels into the
graft. A. An illustration of murine blood vessels that were stained with a mouse-specific CD31 Ab in an ovarian fragment that was treated with
VEGF165 and removed 3 days after transplantation. The host tissue is identified by the dotted arrow, and the graft is identified by the plain arrow.
B. The quantification of murine blood vessels in the grafted tissue 3 days after transplantation. In the treated mice, 6 of 15 fragments contained
CD31-positive blood vessels compared with only 3 of 14 fragments in the control mice. C. The quantification of murine blood vessels in the
grafted tissue 3 weeks after transplantation. All of the fragments in both the control and treated groups contained CD31-positive blood vessels.
n corresponds to the number of transplanted ovarian fragments that contained murine blood vessels. Scale bar: 200 μm. **Corresponds to a
p value < 0.01. Error bar are SEM.
Henry et al. Reproductive Biology and Endocrinology  (2015) 13:12 Page 7 of 10groups. We previously demonstrated that fibrosis that oc-
curred three weeks after transplantation was partially due to
the freeze-thawing procedure [8]. Therefore, more rapid
revascularisation of the transplant after grafting due to the
pro-angiogenic effect of VEGF165 was not likely to limit the
development of fibrosis.
This study analysed ovarian fragments that were encap-
sulated in a collagen gel that contained VEGF165. Indeed,
given the short half-life time of VEGF and in order to have
a longer local delivery, a matrix containing VEGF was ne-
cessary. In our laboratory, encapsulation of ovarian frag-
ment in a collagen gel had already been developed and
proved efficacious. However, other teams have also study
the release of VEGF in different models like alginate scaf-
fold [41] or fibrin matrix [42-45]. In this study, the results
regarding vascular improvement are in agreement with
those from studies that used different systems, such as the
encapsulation of ovarian fragments in a VEGF168 fibrin
matrix and autologous murine transplantation [42-45].
Additionally, the combined effect of VEGF and basicfibroblast growth factor (bFGF) was found to increase graft
survival in an experimental rabbit model of xenografted hu-
man ovarian tissue by triggering angiogenesis and by redu-
cing apoptosis and fibrosis [45]. The present study
confirmed that VEGF165 triggers the angiogenic process;
however, VEGF165 did not reduce fibrosis or affect follicle
survival.
The pre-existing vasculature can initiate the formation of
new blood vessels either by sprouting, intussusception, or
elongation via the incorporation of circulating endothelial
cells [46]. In the context of the physiological angiogenic
process of folliculogenesis, most of these processes are ef-
fective [47]. Ovarian tissue grafts are exposed to ischemic
damage during the post-transplantation period until the vas-
culature develops. Vascular connections between the host
and an ovarian strip that was grafted into a murine ovary
were observed 5 days after transplantation [13]. To deter-
mine whether the addition of VEGF165 had a beneficial effect
on vascular recruitment and limited the period of tissue hyp-
oxia, transplanted fragments were analysed three days and
Figure 4 The analysis of fibrosis and follicles 3 weeks after transplantation. A. The percentage of fibrotic tissue in the ovarian transplant. B.
Primordial and primary follicle quantification in H&E-stained sections (mean number/mm2). C. An illustration of primordial follicles that were
considered to be morphologically normal (the plain arrow) or abnormal (the dotted arrow) with disorganised granulosa cells. D. The proportion
of morphologically normal and abnormal primordial and primary follicles in the control group and the VEGF165-treated group. n corresponds to
the number of ovarian fragments that were transplanted into mice. Scale bar: 200 μm. Error bar are SEM.
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vealed that VEGF165 effectively improved graft vascularisa-
tion as early as three days post-transplantation. Moreover, a
higher proportion of functional blood vessels (dextran
FITC-positive vessels) and mature vessels (α-SMA) was ob-
served. Using species-specific CD31 immunohistochemistry
and double staining for functional and mature blood vessels
(Dextran-FITC and α-SMA), we demonstrated the dual ori-
gin of angiogenesis (from the host and from the grafted tis-
sue), as previously described [36]. Collectively, these data
confirm the pro-angiogenic effect of VEGF165 and the pres-
ence of murine endothelial cell migration towards the sheep
transplant. However, this improved vascularisation did not
modulate the follicular density and did not alter the follicular
morphology. In this study, follicular morphology was evalu-
ated in several sections using light microscopy scoring as
previously described [24]. VEGF165 was used in this study,
following our encouraging results with VEGF111, because it
offers the advantage, with respect to the 111 isoform, of
existing both in free and matrix-bound forms, which couldimprove its release profile from the collagen matrix.
However, in contrast to VEGF111, which has been demon-
strated to preserve primary ovarian follicles and improve
angiogenesis [23], VEGF165 failed to significantly decrease fi-
brosis or increase oocyte survival and morphology. Various
VEGF isoforms have exhibited differences in mitogenicity,
chemotactic efficacy, receptor interaction, and tissue distri-
bution [48,49]. However, a direct comparison of VEGF111
and VEGF165 in terms of the follicular pool, survival, and
morphology preservation has yet to be performed. Another
key factor that affects the efficacy of cytokine treatments is
the route of administration of these molecules. Skaznik-
Wikiel et al. previously reported that intraperitoneal injec-
tions of VEGF164 for five days combined with subcutaneous
injections of granulocyte colony-stimulating factor (G-CSF)
maintained the primordial follicular pool [43]. In addition,
Friedman et al. found that graft incubation with hyaluronan-
rich biological glue combined with VEGF-A and vitamin E
decreased the number of atretic follicles and the levels of
apoptosis two weeks after grafting in a xenograft model [44].
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ian graft incubation followed by hypodermic injections at
the transplant site with a combination of VEGF and bFGF
7 days after transplantation improved angiogenesis and re-
duced apoptosis and fibrosis 6 weeks after transplantation
[45]. Although these studies have demonstrated the benefi-
cial effects of VEGF, they often used a method of systemic
delivery of VEGF, which is not reasonable in the context of
clinical usage in patients with cancer. The major advantage
of our model was limiting local exposure to VEGF to the site
of transplantation. Other molecules used without VEGF
such as S1P [15], EPO [16], or PRP [17] have been shown to
improve the quality of ovarian grafts and could therefore be
interesting to study in combination with VEGF. Other mole-
cules such as human menopausal gonadotropin (HMG) act
indirectly, increasing endogenous VEGF secretion in a trans-
plant after three hours of culture before grafting. HMG
treatment accelerated revascularisation of the transplant and
increased the number of surviving follicles one month after
transplantation [50]. These data emphasise the potential
benefits of combining different growth factors to prevent
early ischemic damage, improve rapid revascularisation of
the transplant, and maintain the follicular pool.
Conclusions
This study demonstrates that encapsulation of ovarian tis-
sue with VEGF165 in a collagen matrix during xenografting
in mice produces a more rapid onset of functional vessel
formation and earlier revascularisation of the transplant.
Collectively, our data suggest that the prevention of hyp-
oxia during ovarian tissue grafting requires additional co-
factors to preserve the follicular pool.
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